Tokyo, Feb 20, 2006 (JCN) - Sankyo, a group company of Daiichi Sankyo, has announced its plan for pravastatin, a hyperlipidemia drug, in the US. Currently, Sankyo is supplying the bulk drug of pravastatin to Bristol-Myers Squibb (BMS). In line with a forthcoming termination of the exclusive sales period for pravastatin as of April 20, BMS has agreed with Watson Pharmaceuticals on the sales of pravastatin.
